Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy

Journal of Cancer Research and Clinical Oncology(2022)10.1007/s00432-022-04089-9Source: DataRank Database

Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy is a research paper published in Journal of Cancer Research and Clinical Oncology (2022). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.30)OA: greenTopics (42)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Jessica R. Bauman ORCID,Elizabeth A. Handorf ORCID,Eric A. Ross ORCID,Margie L. Clapper ORCID,Joseph Treat

Live enrichment

PubMed:35708776 PMC:PMC10170876 OpenAlex:https://openalex.org/W4283015181

National Cancer Institute

Grant: P30 CA006927

National Cancer Institute

Grant: U54 CA221704(5)

NCI NIH HHS

Grant: U54 CA221705

NCI NIH HHS

Grant: U54 CA221704

NCI NIH HHS

Grant: R01 CA217161

National Institutes of Health

Grant: 5P30CA006927-49

Transgenic Mouse

National Institutes of Health

Grant: 5U54CA221704-04

(2/2) TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership

FWCI

1.30

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10170876/pdf/432_2022_Article_4089.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00432-022-04089-9.pdf

publisherhttps://link.springer.com/article/10.1007/s00432-022-04089-9/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10170876

Fields of Study

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations0301 basic medicine0303 health sciences03 medical and health sciences0302 clinical medicine

MeSH Terms

Progression-Free SurvivalCarcinoma, Non-Small-Cell LungHumansImmunotherapyLung NeoplasmsMutationProto-Oncogene Proteins p21(ras)Receptor Protein-Tyrosine KinasesProto-Oncogene Proteins B-rafB7-H1 AntigenErbB Receptors

Keywords

KRASMedicineInternal medicineOncologyImmunotherapyLung cancerCohortCancerColorectal cancerEGFRNSCLCalkReal-world CohortDriver-mutationProto-Oncogene Proteins B-rafLung NeoplasmsReceptor Protein-Tyrosine KinasesProgression-Free SurvivalB7-H1 AntigenProto-Oncogene Proteins p21(ras)ErbB ReceptorsCarcinoma, Non-Small-Cell LungMutationHumans

Sustainable Development Goals

SDG 0: Good health and well-being